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Background: HER2 positive breast cancer (HER2+ BC) is a heterogeneous disease. Presenting features, patterns of
recurrence and survival of HER2+ BC can differ according to hormone receptors (HR) status. The purpose of this
study is to highlight different gene profile and molecular pathways between HR+ and HR- metastatic HER2+ BCs.  
Material and Methods: 34 HER2+ metastatic BC patients were included: 18 patients with HR+/HER2+ and 14 with
HR-/HER2+. Data regarding tumor characteristics, treatment information and clinical outcomes were collected. The
expression of 770 genes and 13 molecular pathways were evaluated by means of Nanostring PanCancer pathway
panel performed on BC formalin-fixed paraffin-embedded tissues from diagnostic core biopsy or surgical resection
specimen.
Results: Gene expression analysis identified 118 genes with significantly different expression in the two cohorts. All
but one of these genes were over-expressed; only the gene CACNG6 was down-regulated in HR+/HER2+ group. In
particular, 93 genes were over-expressed in HR-/HER2+ while 24 were overexpressed in HR+/HER2+. Most of these
genes encoded growth factors, pro- or anti-inflammatory interleukins and DNA repair factors. 62% of these genes
were involved in PI3K, MAPK and RAS pathways (32, 22 and 18, respectively). PI3K, MAPK and NOTCH pathways
were differently expressed between HR+/HER2+ and HR-/HER2+ (p=0.003, p=0.0018, p=0.02, respectively). All
these three pathways were overexpressed in HR-/HER2+ BC. In particular, all the significantly different expression
genes in NOTCH pathways were overexpressed in HR-/HER2+ group.
Conclusions: This genome expression analysis identified a gene expression profile able to differentiate HR+ versus
HR- HER2+ metastatic BC. The overexpression of PI3K, MAPK and NOTCH pathways in HR-/HER2+ BC could
justify its more aggressive behaviour. The validation of this HER2+ BC profile needs further investigation.
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